Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dow

Showing results (31-40 of 164) with videos related to

Pageof 17
Sort By:
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|January 2, 2013
Listening to youth: Adolescents' reasons for substance use as a unique predictor of treatment response and outcomeSarah J Dow, John F Kelly
Thorax|May 1, 1980
Contemporary mediastinal tuberculosisT J Bloomberg, C J Dow
British Journal of Clinical Pharmacology|June 1, 1976
Ethanol oxidizing enzyme activites in liver diseaseJ Dow, N Krasner, A Goldberg
British Journal of Urology|November 1, 1990
Dilatation in the duplex kidney: 3 unusual casesJ E Page, C J Dow
British Medical Journal|August 27, 2010
A COMPARATIVE STUDY OF CHEST RADIOGRAMS AND THE MANTOUX TEST IN CHILDREND J Dow, W E Lloyd
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1996
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonistsP Sanwald, M David, J Dow
Journal of Clinical Pharmacology|August 1, 1981
The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapyG J Dow, F H Meyers
Lancet (London, England)|March 19, 2010
Electroencephalographic changes in migraine; review of 51 casesD J DOW, C W M WHITTY
Journal of Pharmaceutical Sciences|July 1, 1996
Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dogJ Dow, G F Francesco, C Berg
Clinical Science|June 1, 1971
A suggested method for assessing impairment of myocardial blood flow in patients undergoing selective coronary arteriographyD C Fluck, J Crawley, J Dow
Pageof 17

Showing results (31-40 of 164) with videos related to

Sort By:
Pageof 17
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|January 2, 2013
Listening to youth: Adolescents' reasons for substance use as a unique predictor of treatment response and outcomeSarah J Dow, John F Kelly
Thorax|May 1, 1980
Contemporary mediastinal tuberculosisT J Bloomberg, C J Dow
British Journal of Clinical Pharmacology|June 1, 1976
Ethanol oxidizing enzyme activites in liver diseaseJ Dow, N Krasner, A Goldberg
British Journal of Urology|November 1, 1990
Dilatation in the duplex kidney: 3 unusual casesJ E Page, C J Dow
British Medical Journal|August 27, 2010
A COMPARATIVE STUDY OF CHEST RADIOGRAMS AND THE MANTOUX TEST IN CHILDREND J Dow, W E Lloyd
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1996
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonistsP Sanwald, M David, J Dow
Journal of Clinical Pharmacology|August 1, 1981
The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapyG J Dow, F H Meyers
Lancet (London, England)|March 19, 2010
Electroencephalographic changes in migraine; review of 51 casesD J DOW, C W M WHITTY
Journal of Pharmaceutical Sciences|July 1, 1996
Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dogJ Dow, G F Francesco, C Berg
Clinical Science|June 1, 1971
A suggested method for assessing impairment of myocardial blood flow in patients undergoing selective coronary arteriographyD C Fluck, J Crawley, J Dow
Pageof 17